Salvage treatment experience in advanced synovial sarcoma: A multicenter retrospective analysis of the Anatolian Society of Medical Oncology

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5185-5188

  Yetisyigit, Tarkan ^a   Arpaci, Erkan ^b   Seber, Erdogan Selcuk ^c   Kucukoner, Mehmet ^d   Kos, Fatma Tugba ^e   Sonmez, Ozlem Uysal ^b   Alici, Suleyman ^f   Akman, Tulay ^g   Aktas, Bilge ^c   Yildiz, Ramazan ^h   Gunaydin, Yusuf ⁱ   Inanc, Mevlude ^a   Demirci, Umut ⁱ   Alkis, Necati ^b   Gumus, Mahmut ^h  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

^b Dr Abdurrahman Yurtaslan Education and Research Hospital   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d DICLE UNIVERSITY   (Turkey)

^e ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f MEDICAL PARK HOSPITAL   (Turkey)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

ⁱ GAZI UNIVERSITY   (Turkey)

Author keywords

Advanced disease; Metastasectomy; Prognostic factors; Salvage chemotherapy; Synovial sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MEDICAL SOCIETY; METASTASIS RESECTION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; ONCOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SARCOMA, SYNOVIAL; SEX DIFFERENCE; SURVIVAL RATE; TURKEY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; METASTASECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SARCOMA, SYNOVIAL; SEX FACTORS; SOCIETIES, MEDICAL; SURVIVAL RATE; TURKEY; YOUNG ADULT;

EID: 84887582433     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5185     Document Type: Article

References (16)

1. Bramwell VH, Anderson D, Charette ML (2003). Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev, 3, 3293.
2. Canter RJ, Qin LX, Maki RG, et al (2008). A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res, 14, 8191-7.
3. Elias AD (1994). Salvage therapy for soft tissue sarcomas. Semin Oncol, 4, 76-81.
4. Ferrari A, De Salvo GL, Dall'Igna P, et al (2012). Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer, 48, 3448-55.
5. Hensley ML, Maki R, Venkatraman E, et al (2002). Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 20, 2824-31.
6. Karavasilis V, Seddon BM, Ashley S, et al (2008). Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer, 112, 1585-91.
7. Kaya AO, Buyukberber S, Ozkan M, et al (2012). Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev, 13, 463-7.
8. Lee EM, Rha SY, Lee J, Park KH, Ahn JH (2012). Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Cancer Chemother Pharmacol, 69, 635-42.
9. Palmerini E, Staals EL, Alberghini M, et al (2009). Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer, 115, 2988-98.
10. Potter DA, Glenn J, Kinsella T, et al (1985). Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol, 3, 353-66.
11. Shi W, Indelicato DJ, Morris CG, et al (2013). Long-term treatment outcomes for patients with synovial sarcoma: a 40-year experience at the University of Florida. Am J Clin Oncol, 36, 83-8.
12. Sleijfer S, Ouali M, van Glabbeke M, et al (2010). Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer, 46, 72-83.
13. Spurrell EL, Fisher C, Thomas JM, Judson IR (2005). Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol, 16, 437-44.
14. Trassard M, Le Doussal V, Hacene K, et al (2001). Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol, 19, 525-34.
15. van Geel AN, Pastorino U, Jauch KW, et al (1996). Surgical treatment of lung metastases: the European organization for research and treatment of cancer-soft tissue and bone sarcoma group study of 255 patients. Cancer, 77, 675-82.
16. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al (1999). Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European organization for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol, 17, 150-7.